CHEK1 and acute myeloid leukemia: The dual‐target CHK1/FLT3 inhibitor TLX83 can overcome adaptive and acquired resistance to FLT3 inhibitors, offering a new strategy for patients with FLT3‐ITD‐mutant acute myeloid leukemia (AML).415